Tumor size, stage and grade alterations of urinary peptidome in RCC

Clizia Chinello, Marta Cazzaniga, Gabriele Sio, Andrew James Smith, Angelica Grasso, Bernardo Rocco, Stefano Signorini, Marco Grasso, Silvano Bosari, Italo Zoppis, Giancarlo Mauri, Fulvio Magni

Research output: Contribution to journalArticle

Abstract

Background: Several promising biomarkers have been found for RCC, but none of them has been used in clinical practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data. Methods: A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC-ESI-MS/MS. Results: Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concentration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified. Conclusions: We identified several peptides whose urinary abundance varied according to tumour size, stage and grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients.

Original languageEnglish
Article number332
JournalJournal of Translational Medicine
Volume13
Issue number1
DOIs
Publication statusPublished - Oct 20 2015

Fingerprint

Tumors
Peptides
Neoplasms
Biomarkers
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Proteomics
Carcinogenesis
Urine
Growth

Keywords

  • Cancer
  • Grade
  • Mass spectrometry
  • Peptidomics
  • Proteomics
  • Renal cell carcinoma
  • Stage
  • Tumour progression
  • Tumour size
  • Urine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Chinello, C., Cazzaniga, M., Sio, G., Smith, A. J., Grasso, A., Rocco, B., ... Magni, F. (2015). Tumor size, stage and grade alterations of urinary peptidome in RCC. Journal of Translational Medicine, 13(1), [332]. https://doi.org/10.1186/s12967-015-0693-8

Tumor size, stage and grade alterations of urinary peptidome in RCC. / Chinello, Clizia; Cazzaniga, Marta; Sio, Gabriele; Smith, Andrew James; Grasso, Angelica; Rocco, Bernardo; Signorini, Stefano; Grasso, Marco; Bosari, Silvano; Zoppis, Italo; Mauri, Giancarlo; Magni, Fulvio.

In: Journal of Translational Medicine, Vol. 13, No. 1, 332, 20.10.2015.

Research output: Contribution to journalArticle

Chinello, C, Cazzaniga, M, Sio, G, Smith, AJ, Grasso, A, Rocco, B, Signorini, S, Grasso, M, Bosari, S, Zoppis, I, Mauri, G & Magni, F 2015, 'Tumor size, stage and grade alterations of urinary peptidome in RCC', Journal of Translational Medicine, vol. 13, no. 1, 332. https://doi.org/10.1186/s12967-015-0693-8
Chinello C, Cazzaniga M, Sio G, Smith AJ, Grasso A, Rocco B et al. Tumor size, stage and grade alterations of urinary peptidome in RCC. Journal of Translational Medicine. 2015 Oct 20;13(1). 332. https://doi.org/10.1186/s12967-015-0693-8
Chinello, Clizia ; Cazzaniga, Marta ; Sio, Gabriele ; Smith, Andrew James ; Grasso, Angelica ; Rocco, Bernardo ; Signorini, Stefano ; Grasso, Marco ; Bosari, Silvano ; Zoppis, Italo ; Mauri, Giancarlo ; Magni, Fulvio. / Tumor size, stage and grade alterations of urinary peptidome in RCC. In: Journal of Translational Medicine. 2015 ; Vol. 13, No. 1.
@article{fc487bfcbdd44b479906e3ad32f3a302,
title = "Tumor size, stage and grade alterations of urinary peptidome in RCC",
abstract = "Background: Several promising biomarkers have been found for RCC, but none of them has been used in clinical practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data. Methods: A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC-ESI-MS/MS. Results: Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concentration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified. Conclusions: We identified several peptides whose urinary abundance varied according to tumour size, stage and grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients.",
keywords = "Cancer, Grade, Mass spectrometry, Peptidomics, Proteomics, Renal cell carcinoma, Stage, Tumour progression, Tumour size, Urine",
author = "Clizia Chinello and Marta Cazzaniga and Gabriele Sio and Smith, {Andrew James} and Angelica Grasso and Bernardo Rocco and Stefano Signorini and Marco Grasso and Silvano Bosari and Italo Zoppis and Giancarlo Mauri and Fulvio Magni",
year = "2015",
month = "10",
day = "20",
doi = "10.1186/s12967-015-0693-8",
language = "English",
volume = "13",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Tumor size, stage and grade alterations of urinary peptidome in RCC

AU - Chinello, Clizia

AU - Cazzaniga, Marta

AU - Sio, Gabriele

AU - Smith, Andrew James

AU - Grasso, Angelica

AU - Rocco, Bernardo

AU - Signorini, Stefano

AU - Grasso, Marco

AU - Bosari, Silvano

AU - Zoppis, Italo

AU - Mauri, Giancarlo

AU - Magni, Fulvio

PY - 2015/10/20

Y1 - 2015/10/20

N2 - Background: Several promising biomarkers have been found for RCC, but none of them has been used in clinical practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data. Methods: A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC-ESI-MS/MS. Results: Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concentration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified. Conclusions: We identified several peptides whose urinary abundance varied according to tumour size, stage and grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients.

AB - Background: Several promising biomarkers have been found for RCC, but none of them has been used in clinical practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data. Methods: A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC-ESI-MS/MS. Results: Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concentration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified. Conclusions: We identified several peptides whose urinary abundance varied according to tumour size, stage and grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients.

KW - Cancer

KW - Grade

KW - Mass spectrometry

KW - Peptidomics

KW - Proteomics

KW - Renal cell carcinoma

KW - Stage

KW - Tumour progression

KW - Tumour size

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=84945182108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945182108&partnerID=8YFLogxK

U2 - 10.1186/s12967-015-0693-8

DO - 10.1186/s12967-015-0693-8

M3 - Article

AN - SCOPUS:84945182108

VL - 13

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 332

ER -